Biochemical characterization of LR769, a new recombinant factor VIIa bypassing agent produced in the milk of transgenic rabbits
Open Access
- 8 June 2017
- journal article
- Published by Wiley in Haemophilia
- Vol. 23 (4), e324-e334
- https://doi.org/10.1111/hae.13253
Abstract
The bypassing agent factor VII (FVIIa) is a first-line therapy for the treatment of acute bleeding episodes in patients with haemophilia and high-titre inhibitors. FVIIa is a highly post-translationally modified protein that requires eukaryotic expression systems to produce a fully active molecule. A recombinant FVIIa was produced in the milk of transgenic rabbits to increase expression and provide an efficient, safe and affordable product after purification to homogeneity (LR769). To present the biochemical and functional in vitro characteristics of LR769. Mass spectrometric analyses of the intact protein and of heavy and light chains revealed a fully activated, mature and properly post-translationally modified protein notably regarding N/O-glycosylations and γ-carboxylation. Primary structure analysis, performed by peptide mapping, confirmed 100% of the sequence and the low level or absence of product-derived impurities such as oxidized, deamidated and glycated forms. Low levels of aggregates and fragments were observed by different chromatographic methods. Higher order structure investigated by circular dichroism showed appropriate secondary/tertiary structures and conformational change in the presence of Ca2+ ions. Finally, activated partial thromboplastin time and thrombin generation assays showed the ability of LR769 to decrease coagulation time and to generate thrombin in haemophiliac-A-plasmas, even in the presence of inhibitors. The innovative expression system used to produce LR769 yields a new safe and effective rhFVIIa for the treatment of haemophilia A or B patients with inhibitors.Keywords
Funding Information
- LFB Biotechnologies
This publication has 38 references indexed in Scilit:
- N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbitsGlycobiology, 2013
- Production of pharmaceutical proteins by transgenic animalsComparative Immunology, Microbiology and Infectious Diseases, 2009
- A Perspective on the Maillard Reaction and the Analysis of Protein Glycation by Mass Spectrometry: Probing the Pathogenesis of Chronic DiseaseJournal of Proteome Research, 2008
- In vitro stability of two formulations of recombinant activated factor viia reconstituted in inappropriate solvents or at inappropriate volumesClinical Therapeutics, 2008
- Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decisionHaemophilia, 2005
- Conformational Stability of Factor VIIa: Biophysical Studies of Thermal and Guanidine Hydrochloride-Induced DenaturationBiochemistry, 1998
- Site-directed mutagenesis but not γ-carboxylation of Glu-35 in factor VIIa affects the association with tissue factorFEBS Letters, 1996
- The Use of RP‐HPLC for measuring activation and cleavage of rFVIIa during purificationBiotechnology & Bioengineering, 1995
- FVIIa derivatives obtained by autolytic and controlled cathepsin G mediated cleavageFEBS Letters, 1993
- Circular dichroism analysis of the secondary structures of bovine blood coagulation factor IX, factor X, and prothrombinJournal of Protein Chemistry, 1988